{"id":85681,"date":"2026-05-12T13:26:13","date_gmt":"2026-05-12T07:56:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=85681"},"modified":"2026-05-12T13:26:15","modified_gmt":"2026-05-12T07:56:15","slug":"corona-remedies-q4-results-fy26-pat-jumps-44-percent","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/corona-remedies-q4-results-fy26-pat-jumps-44-percent\/","title":{"rendered":"Corona Remedies Q4 Results FY26 PAT Jumps 44 Percent Dividend Rs 10 Per Share Pharma Chronic Segments Outperform"},"content":{"rendered":"
\u00a0<\/div>\n

Corona Remedies<\/a> Q4 results FY26 reported quarterly profit after tax jumping 44% year on year for Q4 FY26, continuing the company consistent outperformance versus the Indian Pharmaceutical Market (IPM). The Corona Remedies Q4 results were announced on May 11, 2026, with the board declaring a final dividend of Rs 10 per equity share for FY26.<\/p>\n

For full fiscal year FY26, the Corona Remedies Q4 results cap a strong year building on Q2 FY26 PAT of Rs 52.32 crore and H1 FY26 PAT of Rs 98.52 crore. The Corona Remedies Q4 FY26 EBITDA margins have consistently exceeded 21% across FY26. The company acquired Wokadine from Dr. Reddys Laboratories effective March 30, 2026, entering the Rs 648 crore povidone iodine market, and also acquired seven brands from Bayer Zydus for approximately Rs 7.5-8 crore.<\/p>\n

Get Free Stock Recommendations on Univest<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n